Investigation of the factors that affect Aricept medication persistence rate and the safety and efficacy in patients with Alzheimer's Disease in clinical practice
Not Applicable
- Conditions
- Alzheimer's Disease
- Registration Number
- JPRN-jRCT1080222138
- Lead Sponsor
- Eisai Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 10000
Inclusion Criteria
Patients diagnosed as Alzheimer's Disease and administered Aricept for the first time.
Exclusion Criteria
Patients with a history of hypersensitivity to any ingredients of Aricept or piperidine derivatives.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cognitive function<br><br>MMSE or HDS-R
- Secondary Outcome Measures
Name Time Method